Ultra-deep T cell receptor sequencing reveals the complexity and intratumour heterogeneity of T cell clones in renal cell carcinomas

Marco Gerlinger, Sergio A Quezada, Karl S Peggs, Andrew JS Furness, Rosalie Fisher, Teresa Marafioti, Vishvesh H Shende, Nicholas McGranahan, Andrew J Rowan, Steven Hazell, David Hamm, Harlan S Robins, Lisa Pickering, Martin Gore, David L Nicol, James Larkin and Charles Swanton

1 Cancer Research UK, London Research Institute, UK
2 Barts Cancer Institute, Barts and the London School of Medicine and Dentistry, London, UK
3 UCL Cancer Institute, London, UK
4 Royal Marsden Hospital, London, UK
5 Departments of Pathology and Histopathology, University College Hospital, London, UK
6 Centre for Mathematics and Physics in the Life Sciences and Experimental Biology (CoMPLEX), University College London, UK
7 Adaptive Biotechnologies, Seattle, WA, USA
8 Fred Hutchinson Cancer Research Center, Seattle, WA, USA

*Correspondence to: C Swanton, Cancer Research UK, London Research Institute, 44 Lincoln’s Inn Fields, London WC2A 3LY, UK. E-mail: charles.swanton@cancer.org.uk

Abstract

The recognition of cancer cells by T cells can impact upon prognosis and be exploited for immunotherapeutic approaches. This recognition depends on the specific interaction between antigens displayed on the surface of cancer cells and the T cell receptor (TCR), which is generated by somatic rearrangements of TCRα- and β-chains (TCRβ). Our aim was to assess whether ultra-deep sequencing of the rearranged TCRβ in DNA extracted from unfractionated clear cell renal cell carcinoma (ccRCC) samples can provide insights into the clonality and heterogeneity of intratumoural T cells in ccRCCs, a tumour type that can display extensive genetic intratumour heterogeneity (ITH). For this purpose, DNA was extracted from two to four tumour regions from each of four primary ccRCCs and was analysed by ultra-deep TCR sequencing. In parallel, tumour infiltration by CD4, CD8 and Foxp3 regulatory T cells was evaluated by immunohistochemistry and correlated with TCR-sequencing data. A polyclonal T cell repertoire with 367–16 289 (median 2394) unique TCRβ sequences was identified per tumour region. The frequencies of the 100 most abundant T cell clones/tumour were poorly correlated between most regions (Pearson correlation coefficient, –0.218 to 0.465). 3–93% of these T cell clones were not detectable across all regions. Thus, the clonal composition of T cell populations can be heterogeneous across different regions of the same ccRCC and was analysed by ultra-deep TCR sequencing. In parallel, tumour infiltration by CD4, CD8 and Foxp3 regulatory T cells was evaluated by immunohistochemistry and correlated with TCR-sequencing data. A polyclonal T cell repertoire with 367–16 289 (median 2394) unique TCRβ sequences was identified per tumour region. The frequencies of the 100 most abundant T cell clones/tumour were poorly correlated between most regions (Pearson correlation coefficient, –0.218 to 0.465). 3–93% of these T cell clones were not detectable across all regions. Thus, the clonal composition of T cell populations can be heterogeneous across different regions of the same ccRCC. T cell ITH was higher in tumours pretreated with an mTOR inhibitor, which could suggest that therapy can influence adaptive tumour immunity. These data show that ultra-deep TCR-sequencing technology can be applied directly to DNA extracted from unfractionated tumour samples, allowing novel insights into the clonality of T cell populations in cancers. These were polyclonal and displayed ITH in ccRCC. TCRβ sequencing may shed light on mechanisms of cancer immunity and the efficacy of immunotherapy approaches.

Keywords: cancer immunity; biomarker; immunotherapy; T cell; intratumour heterogeneity

Conflicts of interest: DH is a full-time employee of Adaptive Biotechnologies, receiving salary and stock options. HRS receives consulting fees and owns stock in Adaptive Biotechnologies. There are no other conflicts of interest.

Introduction

T cells can infiltrate solid tumours and recognize peptide antigens presented on the surface of cancer cells by MHC molecules. Such antigen-specific adaptive T cell immune responses can be directed towards self antigens [1–4] as well as neo-antigens (or ‘mutated self-antigens’) generated by somatic mutations in the cancer genome [5,6]. T cells directed towards cancer cells can significantly impact upon clinical outcome, as shown by a number of studies that have found a correlation between increased numbers of tumour-infiltrating lymphocytes and improved survival in a variety of tumour types [7]. More recently, immunotherapeutic approaches based on antibody-mediated blockade of co-inhibitory receptors expressed on activated T cells (CTLA4 and PD-1) have been shown to produce durable responses, even in some patients with highly pretreated solid tumours, including ccRCC [8–10]. Whilst a large number of studies have focused on understanding the mechanisms regulating T cell function within the tumour microenvironment,
the clonal complexity of the T cell response in solid tumours throughout progression and therapy, and the potential utility of the T cell clonality patterns as a prognostic or predictive biomarker capable of informing choice of therapy, remain unexplored.

The repertoire of antigen-specific T cells is generated during T cell differentiation in the thymus, by somatic recombination of the T cell receptor α- and β-chains [11]. Rearrangement of V, D and J segments in the TCRb generates the highly variable complementary determining region 3 (CDR3) critical to determine the specificity of each particular T cell clone. ImmunoSEQ-technology allows ultra-deep sequencing of the TCRb CDR3 region and reveals the clonal composition of T cell populations [12]. This ultra-deep TCR-sequencing method has been applied to DNA extracted from purified immune cell samples to define the T cell repertoires in the blood of healthy individuals [13], during viral infections [14] or following treatment for leukaemia [15]. More recently, this technology has been used to interrogate T cell clonality directly from the DNA extracted from unfraccionated cancer samples, which contain a mixture of cancer and stroma cells as well as lymphocytes [16]. However, some tumour types, such as clear cell renal cell carcinomas (ccRCCs), can display extensive genetic intratumour heterogeneity [17,18] which, as seen for other cancers [19,20], is likely to generate neo-antigens with a heterogeneous distribution throughout the tumour. Our aim was to analyse multiple samples from individual ccRCCs with ultra-deep TCR-sequencing to determine whether T cell infiltrates were uniform or heterogeneous across different regions of the same tumour. Deciphering the heterogeneity of the T cell repertoire within individual tumours may have important implications for future biomarker discovery immunotherapy studies.

Materials and methods

All patients had been diagnosed with stage IV renal ccRCCs. One of the included patients was treatment-naïve, one had been pretreated with sunitinib for 16 weeks and two further patients had been treated on the EPREDECT trial (EudraCT No. 2009-013381-54) with 6 weeks of pre-operative everolimus, followed by a nephrectomy. The translational research study presented here had been approved by an ethics review board and all patients had provided written informed consent for participation. Multiple tumour specimens were collected as described previously [17]. In brief, the nephrectomy specimen was dissected by a uro-oncology pathologist and different regions, representing the spatial extent and macroscopic heterogeneity of each primary tumour, were harvested (each ca. 5 × 5 × 5 mm in size) and snap-frozen in liquid nitrogen within 1 h after surgical resection of the primary ccRCC. DNA was extracted and three or four samples/tumour with a good DNA yield were chosen for TCRb sequencing. 2 µg DNA, or lower amounts from tumour regions with restricted DNA availability (for details see Table 1), were sent to Adaptive Biotechnology (Seattle, USA). Adaptive Biotechnology performed the ‘survey’ level ImmunoSEQ assay [12] on each sample. The resulting sequence data was processed and uploaded onto the ImmunoSEQ Analyser web-based relational database for analysis. Sequencing error correction, as previously described [12], was applied automatically by the analysis platform to support the precise quantification of rare T cell clones [21]. Data were normalized for PCR bias as recommended by Adaptive Biotechnologies and regional TCRb sequences defining individual T cell clones and their regional abundance were downloaded from the webpage for the analyses specified. We used the Spearman’s rank test to assess the relationship between total TCRb reads and immunohistochemical T cell infiltrate across all regions from all tumours. A linear regression function was computed after exclusion of data from R6 RMH002, which was a single outlier in the dataset. All other correlations were analysed by the Pearson correlation coefficient method. The statistical significance of the difference in TCR reads between everolimus-treated and untreated samples was determined by a two-sided t-test.

Paraffin-embedded tissue sections of different regions from all four cases were investigated by multi-immunoenzymatic staining, following protocols previously described [22,23]. The antibodies used in this study were anti-human mouse monoclonals and included: FoxP3 (clone 236A/E7; Abcam, Cambridge, UK); CD4 (clone 4B12; Leica Microsystems, Newcastle upon Tyne, UK); and CD8 (clone C8/144B; Dako, Ely, UK). Scanned slide images were obtained with use of NanoZoomer Digital Pathology System (Hamamatsu, Japan) and individual T cell populations were quantified with use of ImageJ software on 10 representative areas/tumour section at ×40 magnification. Counting of positive cells was performed in a blinded manner by AF, TM and SAQ. Representative images of each section were acquired on a Nikon Eclipse E400 microscope equipped with ×10/0.30 and ×40/0.75 Plan Fluor objective lenses, using a Nikon DS-5Mc digital camera (all Nikon, Tokyo, Japan) and Adobe Photoshop CS4 image processing software (Adobe, San Jose, CA, USA).

Results

DNA was extracted from three or four different tumour regions from each of the four primary ccRCCs. One of these tumours was treatment-naïve (RMH004), one had been treated for 16 weeks before surgery with the anti-angiogenic drug sunitinib (RMH002) and two had been treated with the mammalian target of rapamycin (mTOR) inhibitor everolimus for 6 weeks before the tumours were removed by surgery (EV003
Table 1. Patient characteristics and TCRβ CDR3 sequencing metrics (staging is based on the 6th TNM edition). The maximum tumour diameter was measured on fresh specimens dissected through the long axis.

| Patient | Pathological characteristics and prior therapy | Region | Location within the tumour | Input DNA (ng) | Total TCRβ reads | Productive TCRβ reads | Unique TCRβ reads | Highest frequency clone (%) |
|---------|---------------------------------------------|--------|-----------------------------|----------------|-----------------|----------------------|-------------------|--------------------------|
| RMH002  | Stage T3N0M1, max. diameter 10 cm, grade 2–4, Suni-treated | R2     | Superior pole                | 2 000          | 3 069 283      | 2 615 838            | 14 563           | 2.02                     |
|         | Age 63 years, male                           |        |                              |                |                 |                      |                   |                          |
|         | RMH004                                      | R6     | Centre                       | 2 000          | 1 334 098      | 1 183 323            | 15 730           | 2.58                     |
|         | Stage T4N0M1, max. diameter 14 cm, grade 1–4, treatment-naive | R2     | Lateral pole                 | 1 600          | 1 995 175      | 1 736 371            | 6 669            | 3.54                     |
|         | Age 61 years, male                           | R5     | Inferior pole                | 1 290          | 2 150 919      | 1 899 305            | 16 289           | 1.65                     |
|         | EV003                                        | R7     | Infero-medial                | 2 000          | 1 777 482      | 1 486 505            | 3 663            | 3.90                     |
|         | Stage T3N0M1, max. diameter 8 cm, grade 1–4, Everolimus-treated | R1     | Centre                       | 2 000          | 492 104        | 406 374              | 569              | 3.81                     |
|         | Age 64 years, female                         | R3     | Medial pole                  | 2 000          | 702 016        | 618 863              | 953              | 1.01                     |
|         | EV004                                        | R6     | Superior pole                | 2 000          | 1 042 005      | 891 378              | 6 717            | 7.07                     |
|         | Stage T2N0M1, max. diameter 10 cm, grade 1–2, Everolimus-treated | R10    | Lateral Pole                 | 2 000          | 606 868        | 513 132              | 1 385            | 1.66                     |
|         | Age 57 years, female                         | R2     | Infero-lateral               | 2 000          | 243 119        | 199 725              | 1 237            | 2.89                     |
|         |                                              | R3     | Infero- medial               | 471            | 910 205        | 838 404              | 1 752            | 10.61                    |
|         |                                              | R4     | Medial pole                  | 1 873          | 460 035        | 372 847              | 367              | 4.22                     |
|         |                                              | R6     | Anterior pole                | 1 829          | 433 774        | 327 218              | 719              | 22.83                    |

Table 2. T cell infiltrate per tumour region based on immunohistochemistry. T cell subtypes are shown as percentages of the total count.

| Total lymphocyte count | CD8+ (%) | CD4+ (%) | CD4+FoxP3+ (%) |
|------------------------|----------|----------|----------------|
| RMH002 R2              | 34.2     | 58.0     | 7.7           |
| R6                     | 53.57    | 41.6     | 5.8           |
| RMH004 R2              | 38.4     | 52.5     | 9.1           |
| R5                     | 43.4     | 40.1     | 16.5          |
| R7                     | 37.7     | 48.2     | 14.1          |
| EV003 R1               | 58.8     | 23.4     | 17.8          |
| R3                     | 53.1     | 46.9     | 0.0           |
| R3                     | 27.3     | 68.9     | 3.8           |
| R6                     | 26.9     | 61.3     | 11.8          |
| EV004 R2               | 48.8     | 46.3     | 4.9           |
| R3                     | 67.2     | 30.4     | 2.4           |
| R4                     | 30.5     | 63.6     | 5.9           |
| R6                     | 22.9     | 73.9     | 3.2           |
were removed. Only the remaining ‘productive TCRs sequences’ were used in further analyses. The total number of detected unique productive TCR sequences (each of them defining a unique T cell clone) per tumour region was between 367 and 16 289 (Table 1), indicating that intratumoural T cell populations were highly polyclonal in these ccRCCs. The median frequency of all individual T cell clones detected/tumour was in the range 0.0015–0.013%, demonstrating that the vast majority of T cell clones were present at low frequencies in each tumour (Figure 2). Only 0.27–6.27% of T cell clones in a single tumour were expanded to at least 0.25% of the T cell population in at least one tumour region (Figure 2). The maximum frequency of an individual T cell clone in a tumour region was 22.84% (detected in R6 of EV004) and in the range 2.58–7.07% in all other tumours (Table 1). These data would be consistent with a scenario where only a small number of T cell clones in each tumour expands to higher frequencies. Whilst this technology does not distinguish tumour-reactive T cells, the expansion of particular T cells clones could potentially be driven by their cognate antigen. In contrast, the majority of T cell clones, present at low frequencies, may be either low-affinity clones incapable of expanding in response to antigen or non-tumour reactive bystander lymphocytes.

Our next aim was to compare the TCR repertoire across multiple regions from each tumour to assess whether T cell populations in ccRCCs are spatially heterogeneous. Sequences which were detected in all regions from an individual tumour were classified as ubiquitous and all other T cell clones as heterogeneous. Only 0.24–16.82% of all T cell clones found in an individual tumour were detected ubiquitously in all regions (Table 3), whereas the majority of T cell clones were heterogeneous and, within the limits of our assay, spatially separated. Each sample had been sequenced to a depth in excess of several hundred thousand reads to allow the detection of low-frequency T cell clones (Table 1). However, the human T cell repertoire can be highly complex. For example, over one million unique TCRb sequences have been detected in the peripheral blood of an individual [24] and the theoretical number of different TCRb sequences which are expected to circulate in the blood of an adult is around 10 million [13]. Thus, the number of unique T cell clones within a sequenced sample could be higher than the sequencing depth used in our study. This could lead to the failure to detect low-frequency T cell clones which may be present in a sample through random sampling effects, as previously described [21], and would result in an overestimation of intratumoural TCR repertoire heterogeneity.

Therefore, in order to attempt to avoid the potential impact of low-frequency clone sampling bias, we re-assessed heterogeneity, including only the 100 T cell clones found with the highest regional frequency across each of the four tumours; 3–93% of the 100 most abundant T cell clones in each tumour were still not ubiquitously detectable across all regions (Table 3).
Figure 2. Histogram of T cell clone frequencies. The bin boundaries shown on the x axis represent the maximum regional frequency of the T cell clones in percent and are on a log 2 scale; the y axis shows the number of T cell clones in each frequency bin. The median percentage of all T cell clones/tumour and the percentage of T cell clones with a frequency of 0.25% and above are shown for each tumour.

A heat map of the regional abundance of these T cell clones also demonstrated that the T cell populations found in ccRCCs are spatially heterogeneous and that different clones can be dominant in different tumour regions (Figure 3). Consistently, a Pearson correlation coefficient analysis of the abundance of individual T cell clones in any two regions per tumour revealed a poor correlation (Figure 4) for most pairs. Each of the 100 most abundant T cell clones per tumour was detected in > 2000 sequencing reads or 1.7% of all reads in at least one region (for detailed TCRb-sequences and read counts, see supplementary

Table 3. Intratumour heterogeneity of T cell clones

|                      | Analysis based on all detected T cell clones/tumour | Analysis based on the 100 most frequent T cell clones/tumour |
|----------------------|-----------------------------------------------------|-------------------------------------------------------------|
|                      | RMH002 | RMH004 | EV003 | EV004 | RMH002 | RMH004 | EV003 | EV004 |
| Unique T cell clones | 25.930 | 25.471 | 8809  | 3780  | N/A    |        |       |       |
| Proportion of ubiquitous clones (%) | 16.82 | 1.31  | 0.45  | 0.24  | 97.00  | 67.00  | 16.00 | 7.00  |
| Proportion of heterogeneous clones (%) | 83.18 | 98.69 | 99.55 | 99.76 | 3.00   | 33.00  | 84.00 | 93.00 |
material, Table S1). Previous reproducibility and quality control experiments of TCRb sequencing demonstrated that the quantification of T cell clones with similar abundances are highly reproducible in repeat sequencing experiments from the same sample [21]. Thus, the observed differences in regional frequencies within tumours are unlikely to be the result of detection and quantification biases but are likely to represent true differences between tumour regions. Comparison with clinical and pathological characteristics (Table 1) further demonstrated that heterogeneity was highest in the tumours pretreated for 6 weeks with everolimus, with 84% (EV003) and 93% (EV004) of T cell clones not detectable across all four regions. In comparison, only 33% of T cell clones were not detectable across all four regions from RMH004 and 3% of T cell clones in RMH002 were not detectable across the two sequenced regions. Data were only available from two regions in RMH002, which may explain the limited diversity compared to all other tumours from which four regions had been analysed.

Finally, we investigated whether we could identify any public TCRb sequences among the top 100 T cell clones in two or more patients. This did not identify any shared TCRb nucleotide or amino acid sequences between any of the four patients (data not shown).

**Discussion**

This study shows that the T cell repertoire present in ccRCC tumour samples can be analysed directly by ultra-deep TCRb sequencing technology in DNA extracted from unfractionated specimens. Applied to multiple regions from each of four primary ccRCCs, this demonstrated that intratumoural T cell populations can be highly polyclonal, consistent with previous reports relying on a PCR-based CDR3 length analysis [25]. Correlation analysis of TCRb reads and T cell infiltrates on histological sections validated the ability of ultra-deep TCRb sequencing to measure the abundance of T cells in these specimens. It is conceivable that sequencing based on quantification of intra-tumoural T cells may be more accurate than immunohistochemical methods, as the latter only survey a small section of the tumour, whereas DNA for sequencing analysis was extracted from larger, three-dimensional specimens. This may explain the outlier in Figure 1A, where IHC score and TCR reads show an imperfect correlation.

A number of potentially interesting and important observations can be made from our data, although, given the relatively small number of tumours examined, this is largely hypothesis-generating and requires further confirmation. Several T cell clones/tumour were present at frequencies suggesting clonal expansion, potentially as a response to activation by their cognate antigen. However, the vast majority of individual T cell clones were present at very low frequencies,
suggesting that these clones have not undergone clonal expansion. These clones may not be able to recognize local tumour antigens or the clones may have been suppressed from expansion by virtue of local microenvironmental signals. Alternatively, many of these T cells may be present in the tumour sample because they are circulating through the tumour with the perfusing blood. Careful functional studies and comparisons with the T cell repertoire in the peripheral blood and normal kidney will be necessary to shed further light on this.

Restricting the analysis to the 100 most abundant regional clones/tumour displayed a heterogeneous distribution of individual T cell clones across different tumour regions. The variability in the frequency of individual T cell clones between tumour regions indicates that these clones are most likely infiltrating the tumour tissue and not simply contamination from the perfusing blood. T cells that are present at high levels in the perfusing blood would be expected to be detectable ubiquitously and at similar frequencies across different tumour regions. Exome sequencing of multiple tumour regions from individual ccRCCs recently demonstrated extensive genetic intratumour heterogeneity in these tumours [17,18]. Importantly, heterogeneous subclonal mutations were spatially separated into different tumour regions. Thus, the identification of heterogeneous T cell populations in different tumour regions may indicate that T cell immune responses could be directed at spatially heterogeneous tumour neo-antigens present in distinct regions of these tumours. This demonstrates that multiple biopsies may be required to obtain a comprehensive overview of the response of the immune system to an individual cancer.

Comparison of the 100 most abundant TCRβ sequences across the four cases did not identify any TCRβ nucleotide or amino acid sequences which were shared by different patients. However, the question of whether common antigens are relevant in ccRCCs needs to be assessed in individuals which are matched for their HLA background, which was not the case in our study.

Our observation of a decreased polyclonality, coupled with an increase in the regional heterogeneity of T cell clones in the small number of tumours pretreated with the immunosuppressive mammalian target of rapamycin (mTOR) inhibitor everolimus, compared to the tumours which were untreated or treated with the anti-angiogenic drug sunitinib, may indicate that specific cancer therapies can influence the T cell repertoire and its distribution in solid tumours. Further analyses could be used to identify treatments that accentuate the number and abundance of T cell clones, to assess whether this may be associated with an increase in the efficacy of combination therapy with immune-stimulatory agents.

Our and others’ [16] data demonstrate that ultra-deep TCR sequencing can determine the clonality of T cells directly in DNA extracted from tumour tissues. Large collections of such samples are readily available for many tumour types, and these could be used to compare somatic genetic alterations with the T cell population present in the same sample. This may provide major insights into the parallel evolution and interplay of cancer genetics and the adaptive cellular immune response. For example, this may allow the investigation of immune editing processes, where cancer clones harbouring antigenic mutations may be lost due to eradication by T cells [26], or the analysis of differences in the immune response between poorly and highly immunogenic tumours, such as melanoma or renal cancer. This technology may also be useful to investigate clonality patterns of immune cell infiltrates, which may indicate a high probability of responding to immunotherapy, and the comparison of T cell repertoires of responders and non-responders may reveal how some cancers evade immunotherapy.

Complementary approaches incorporating TCR sequencing, functional studies of T cells extracted from cancer specimens and multicolour immunohistochemistry to analyse different tumour regions may inform therapeutic decisions in the clinic, as these will provide both an understanding of the breadth and quality of the immune response in RCC.

In conclusion, we show that the clonality and abundance of intratumoural T cell populations can be analysed directly from DNA extracted from unfractionated ccRCC specimens. This provides a powerful new tool to investigate the magnitude and diversity of T cell responses in these tumours as potential biomarkers for prognosis and responses to novel immunotherapeutic agents. Similar to the recent identification of genetic and functional intratumour heterogeneity in ccRCC, T cell populations varied between different regions of the same ccRCC, demonstrating intratumour heterogeneity of T cell immunity. Thus, multiple biopsy approaches may be required to fully characterize the immune response to an individual tumour.
References

1. van der Bruggen P, Traversari C, Chomez P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991; 254: 1643–1647.
2. Briche D, Van Pel A, Wolfel T, et al. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 1993; 178: 489–495.
3. Kawasaki Y, Elyahu S, Sakaguchi K, et al. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med 1994; 180: 347–352.
4. Walton SM, Gerlinger M, de la Rosa O, et al. Spontaneous CD8 T cell responses against the melanocyte differentiation antigen RAB38/NY-MEL-1 in melanoma patients. J Immunol 2006; 177: 8212–8218.
5. Heemskerk B, Kivistorg P, Schumacher TN. The cancer antigen. EMBO J 2013; 32: 194–203.
6. Robbins PF, Lu YC, El-Gamil M, et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med 2013; 19: 747–752.
7. Gooden MJ, de Bock GH, Leffers N, et al. The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br J Cancer 2011; 105: 93–103.
8. Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711–723.
9. Lipson EJ, Sharfan WH, Drake CG, et al. Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. Clin Cancer Res 2013; 19: 462–468.
10. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366: 2443–2454.
11. Davis MM, Bjorkman PJ. T-cell antigen receptor genes and T-cell recognition. Nature 1988; 334: 395–402.
12. Robins HS, Campougher PV, Sivastava SK, et al. Comprehensive assessment of T-cell receptor β-chain diversity in αβ T cells. Blood 2009; 114: 4099–4107.
13. Robins HS, Sivastava SK, Campougher PV, et al. Overlap and effective size of the human CD8+ T cell receptor repertoire. Sci Transl Med 2010; 2: 47ra64.
14. Neller MA, Burrows JM, Rist MJ, et al. High frequency of herpesvirus-specific clonotypes in the human T cell repertoire can remain stable over decades with minimal turnover. J Virol 2013; 87: 697–700.
15. Wu D, Sherwood A, Fromm JR, et al. High-throughput sequencing detects minimal residual disease in acute T lymphoblastic leukemia. Sci Transl Med 2012; 4: 134ra163.
16. Sherwood AM, Emerson RO, Scherer D, et al. Tumor-infiltrating lymphocytes in colorectal tumors display a diversity of T cell receptor sequences that differ from the T cells in adjacent mucosal tissue. Cancer Immunol Immunother 2013; 62: 1453–1461.
17. Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012; 366: 883–892.
18. Martinez P, Birkbak NJ, Gerlinger M, et al. Parallel evolution of tumour subclones mimics diversity between tumours. J Pathol 2013; 230: 356–364.
19. Zorn E, Hercend T. A natural cytotoxic T cell response in a spontaneously regressing human melanoma targets a neoantigen resulting from a somatic point mutation. Eur J Immunol 1999; 29: 592–601.
20. Castle JC, Kreiter S, Diekmann J, et al. Exploiting the mutanome for tumor vaccination. Cancer Res 2012; 72: 1081–1091.
21. Robins H, Desmarais C, Mathis J, et al. Ultra-sensitive detection of rare T cell clones. J Immunol Methods 2012; 375: 14–19.
22. Marafioti T, Jones M, Facchetti F, et al. Phenotype and genotype of interfollicular large B cells, a subpopulation of lymphocytes often with dendritic morphology. Blood 2003; 102: 2868–2876.
23. Marafioti T, Paterson JC, Ballabio E, et al. Novel markers of normal and neoplastic human plasmacytoid dendritic cells. Blood 2008; 111: 3778–3792.
24. Warren RL, Freeman JD, Zeng T, et al. Exhaustive T-cell repertoire sequencing of human peripheral blood samples reveals signatures of antigen selection and a directly measured repertoire size of at least 1 million clonotypes. Genome Res 2011; 21: 790–797.
25. Puisieux I, Bain C, Merrouche Y, et al. Restriction of the T-cell repertoire in tumor-infiltrating lymphocytes from nine patients with renal cell carcinoma. Relevance of the CDR3 length analysis for the identification of in situ clonal T-cell expansions. Int J Cancer 1996; 66: 201–208.
26. Matsushita H, Vesely MD, Koboldt DC, et al. Cancer exome analysis reveals a T cell-dependent mechanism of cancer immunoediting. Nature 2012; 482: 400–404.
SUPPLEMENTARY MATERIAL ON THE INTERNET
The following supplementary material may be found in the online version of this article:
Table S1. Read counts across individual tumour regions for the 100 TCRβ DNA sequences found, with the highest regional frequency in each of the four tumours

75 Years ago in the Journal of Pathology...

The canine prostate in relation to normal and abnormal testicular changes
S. Zuckerman and T. McKeown

The incidence of the various serological types of Str. agalactiae in herds of cows in Great Britain
A.W. Stableforth

The classification of staphylococci by precipitation and biological reactions
S. T. Cowan

Experimental symmetrical cortical necrosis of the kidneys produced by staphylococcus toxin: A study of the morbid anatomy and associated circulatory and biochemical changes
S. De Navasquez

To view these articles, and more, please visit:
www.thejournalofpathology.com
Click ‘ALL ISSUES (1892 - 2011)’, to read articles going right back to Volume 1, Issue 1.

The Journal of Pathology
Understanding Disease

© 2013 The Authors. Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland. www.pathsoc.org.uk
www.thejournalofpathology.com